The Role of Extracellular HSP70 in the Function of Tumor-Associated Immune Cells

Manuel Linder and Elke Pogge von Strandmann

Institute for Tumor Immunology, Clinic for Hematology, Immunology, and Oncology, Philipps University of Marburg, Hans-Meerwein-Strasse 3, 35043 Marburg, Germany; manuel.linder@staff.uni-marburg.de
* Correspondence: poggevon@staff.uni-marburg.de; Tel.: +49-6421-282-1640

Simple Summary: The intracellular heat shock protein 70 (HSP70) is essential for cells to respond to stress, for instance, by refolding damaged proteins or inhibiting apoptosis. However, in cancer, HSP70 is overexpressed and can translocate to the extracellular milieu, where it emerged as an important modulator of tumor-associated immune cells. By targeting the tumor microenvironment (TME) through different mechanisms, extracellular HSP70 can trigger pro- or anti-tumorigenic responses. Therefore, understanding the pathways and their consequences is crucial for therapeutically targeting cancer and its surrounding microenvironment. In this review, we summarize current knowledge on the translocation of extracellular HSP70. We further elucidate its functions within the TME and provide an overview of potential therapeutic options.

Abstract: Extracellular vesicles released by tumor cells (T-EVs) are known to contain danger-associated molecular patterns (DAMPs), which are released in response to cellular stress to alert the immune system to the dangerous cell. Part of this defense mechanism is the heat shock protein 70 (HSP70), and HSP70-positive T-EVs are known to trigger anti-tumor immune responses. Moreover, extracellular HSP70 acts as an immunogen that contributes to the cross-presentation of major histocompatibility complex (MHC) class I molecules. However, the release of DAMPs, including HSP70, may also induce chronic inflammation or suppress immune cell activity, promoting tumor growth. Here, we summarize the current knowledge on soluble, membrane-bound, and EV-associated HSP70 regarding their functions in regulating tumor-associated immune cells in the tumor microenvironment. The molecular mechanisms involved in the translocation of HSP70 to the plasma membrane of tumor cells and its release via exosomes or soluble proteins are summarized. Furthermore, perspectives for immunotherapies aimed to target HSP70 and its receptors for cancer treatment are discussed and presented.

Keywords: HSP70; extracellular vesicles; tumor microenvironment; cancer; immune modulation

1. Introduction

Heat shock protein 70 (HSP70/HSPA1A/HSP72) is a molecular chaperone and belongs to the HSP70 family. It is upregulated upon stress-stimuli, such as heat, exercise, or pathological stress. HSP70 comprises a plethora of crucial housekeeping and chaperone activities, including folding of newly synthesized proteins, refolding or disposal of damaged proteins, preventing protein aggregates, or translocating proteins to different compartments. In addition, HSP70 can directly inhibit apoptosis, thus protecting cells from stress-induced cell death [1]. However, in pathologies like cancer, upregulated HSP70 can lead to disease progression and therapy resistance [2]. The chaperone consists of three main domains, the N-terminal ATPase domain (NBD), the substrate-binding domain (SBD), and a C-terminal domain. The NBD is crucial for binding and hydrolyzing ATP to ADP, thus regulating the chaperone’s conformational state. In general, the binding of ATP leads to an open or low-affinity conformation allowing HSP70 to bind its substrates via its SBD.
In the ADP state, the chaperone turns into a closed or high-affinity conformation in which the protein is further protected and processed. Importantly, all functions of HSP70 require different co-chaperones, such as BCI-2-associated anthanogene 3 and 4 (BAG3, BAG4) or carboxy-terminus of HSP70 interacting protein (CHIP), and is mainly mediated by the C-terminal region of the chaperone [1]. Initially, HSP70 was identified as an intracellular protein (iHSP70), but it can translocate to the extracellular milieu (exHSP70) under stressful conditions. This includes physiological stress (e.g., physical activity) and pathological stress (e.g., cancer) and is higher in the latter. Hereby, it is either associated with the plasma membrane (mHSP70), with extracellular vesicles (evHSP70), or secreted as soluble proteins (sHSP70) [2].

Extracellular vesicles (EVs) are nanoparticles secreted by virtually all cells under physiological and pathophysiological conditions. EVs differ in size, origin, and cargo and can be mainly subdivided into ectosomes and exosomes [3]. Ectosomes, also referred to as microvesicles, are generally described as particles with a size of 50–1000 nm, generated by a direct outward budding of the plasma membrane. In contrast, exosomes are small EVs with a size between 40 and 200 nm and are generated along an endosomal pathway by double invagination of the plasma membrane (Box 1). EVs contain a plethora of molecules, including proteins, lipids, and nucleic acids, usually reflecting the cell of origin [3]. In the past, it has been speculated that they function as trash bins to remove unwanted cellular components; however, increasing evidence demonstrates crucial functions as an intercellular communication system [3–5].

Box 1. Biology and function of exosomes

Exosomes are small extracellular vesicles (40–200 nm; small EVs), which are produced by a double invagination of the plasma membrane. In particular, endocytosis leads to the generation of early sorting endosomes (ESE), containing factors from the cell membrane and the extracellular milieu. After maturation to late sorting endosomes (LSE), a second invagination of the membrane occurs, leading to the formation of multivesicular bodies (MVB) containing future exosomes. During MVB formation, cargo is specifically sorted to the vesicles by several distinct mechanisms. The endosomal sorting complexes required for transport (ESCRT) machinery is widely believed to play a role in the sorting process; however, specific loading mechanisms remain largely unknown and need to be elucidated. Typical exosomal markers often include ESCRT components, such as Alix or TSG101. Interestingly, HSP70 is also described as an exosome marker; however, its expression is not specific to the small EVs. The cargo can include various proteins, lipids, or nucleic acids, indicating a multitude of distinct functions. After the release, exosomes can interact with target cells by binding to specific receptors, fusion with the plasma membrane, or endocytosis. Since they are critical players of intercellular communication in physiological and pathological conditions, the research interest significantly increased in the last decade [3,4].

In this review, we summarize the current knowledge on the HSP70 translocation to the extracellular milieu, either in association with the plasma membrane, extracellular vesicles, or as soluble extracellular proteins. Moreover, we outline the functions of exHSP70, especially its ability to modulate the immune system in cancer. We address possible interactions of the chaperone with the tumor microenvironment. Finally, we provide an overview of the potential therapeutic options regarding exHSP70.

2. Translocation of exHSP70

HSP70 has several functions, including folding newly synthesized proteins, regulating protein activity, or preventing aggregation, indicating a cytosolic localization of the chaperone [1]. However, HSP70 has also been found on the plasma membrane, associated with EVs, or secreted as free soluble protein [6–8]. Here, the translocation was shown to occur independently of the physiological state, although stress, such as in cancer, drastically increases the extracellular localization [8,9].

In the classical secretory pathway, proteins synthesized by ribosomes are released into the lumen of the endoplasmic reticulum (ER), where chaperones assist and control the
proper protein folding. Correctly folded proteins subsequently enter the Golgi apparatus and are eventually secreted by transport vesicles. This pathway usually requires a short peptide sequence that targets proteins for secretion [10]. HSP70 lacks such a specific signal peptide indicating different mechanisms for its translocation [11].

2.1. Membrane HSP70 (mHSP70)

In accordance, Broquet and colleagues reported an unhindered translocation of HSP70 to the plasma membrane after treatment with the classical secretory pathway inhibitors brefeldin A or monensin [12]. Brefeldin A is an antiviral lactone compound blocking the anterograde transport from the ER to the Golgi. In contrast, monensin is a polyether antibiotic acting as an ionophore, inhibiting the transport from the Golgi apparatus [13]. This study further revealed that mHSP70 preferentially localizes in lipid rafts, which are microdomains enriched in cholesterol, glycosphingolipids, and protein receptors. They typically form in the exoplasmic leaflet of the Golgi apparatus and are also known as detergent-resistant microdomains (DRMs) due to their composition and resistance to non-ionic detergents [14]. Moreover, treatment with the drug methyl-β-cyclodextrin (MβCD), which degrades cholesterol and disrupts DRMs, resulted in a significant decrease in mHSP70, suggesting lipid raft-mediated translocation of HSP70 [12]. In accordance, Hunter and Levin showed HSP70 release in peripheral blood mononuclear cells (PBMCs), which could be blocked by MβCD but not by brefeldin A [15]. However, in contrast to the previous study, translocation was also partially inhibited by monensin. The authors postulated that the Golgi but not the ER might be important for HSP70 secretion or that monensin led to a disruption of the plasma membrane, ultimately inhibiting the transport [15]. It has also been reported that HSP70 can non-covalently bind to the lipid raft component globotriaosylceramide (Gb3), further supporting the role of lipid rafts in the translocation of the chaperone [16,17]. Therefore, HSP70 could be associated with Gb3 and subsequently secreted and recruited to lipid rafts. Another mechanism of membrane integration by HSP70 could be a direct interaction with the plasma membrane, as suggested by its ability, to bind to phosphatidylserine (PS), integrate into membranes, or form ionic channels [7,18–21]. It has been hypothesized that HSP70 translocates to the membrane after oligomerization, where it binds to PS [7]. Spontaneous flipping allows PS to reach the outer membrane layer, leading to the integration of the chaperone. It is further described that the return of PS into the cytosolic layer does not affect the integration of HSP70 [7].

2.2. EV-Associated HSP70 (evHSP70)

In 2005, Lancaster and co-workers presented another mechanism for the translocation of HSP70 [6]. They reported that HSP70 is released by exosomes in PBMCs independently of stress. Neither brefeldin A nor MβCD were able to inhibit the transport, indicating an endosomal-mediated secretion mechanism. It was further postulated that the controversial results of previous studies in PBMCs from Hunter and Levin could be due to an insufficient concentration of the inhibitor MβCD [6,15]. However, distinct exocytosis processes could occur in different and even within the same cell types. It can be hypothesized that translocation of HSP70 into or onto exosomes could eventuate after the chaperones are localized in DRM. Lipid raft-mediated endocytosis could then lead to the formation of endosomes, further maturing into multivesicular bodies (MVB) containing future exosomes. Many other reports have confirmed exosomal secretion of HSP70; however, the mechanism of sorting the chaperone to the vesicles is still elusive [7,22–24]. In general, posttranslational modifications, including ubiquitination, phosphorylation, or sumoylation, have been indicated to play a role in cargo sorting into exosomes [25–28]. Interestingly, HSP70 was found to be ubiquitinated by the co-chaperone CHIP, mainly presumed to mark the protein for degradation [29,30]. However, Jiang and colleagues showed that ubiquitylation of the constitutive isoform HSC70 by CHIP did not lead to an increased degradation [31]. This is in line with a report displaying that crucial amounts of secreted HSP70 in A431 cells are ubiquitinylated [32]. In contrast, acetylation of the HSP70 family member high
glucose-regulated protein 78 (GRP78) was shown to inhibit exosomal secretion through interaction with the phosphoinositide-3 kinase VPS34 [33]. Acetylated HSP70 was also reported to bind to VPS34 [34]. Hereby, autophagosomal stress led to disruption of the interaction of histone deacetylase 6 (HDAC6) with the chaperone, resulting in increased acetylation. Interestingly, oligomerization, which was shown to play a role in membrane integration of HSP70, was indicated to be preferentially loaded into exosomes [7,35]. This is supported by studies of Nimmervoll and co-workers, demonstrating mHSP70-mediated clathrin-independent endocytosis, which was dependent on the oligomerization of the chaperone [36,37]. Therefore, HSP70 could be sorted into exosomes after integration into the membrane in an oligomeric form.

2.3. Soluble Extracellular HSP70 (sHSP70)

In addition to mHSP70 and evHSP70, the chaperone can also be found in a free soluble form, which was previously thought to result exclusively from passive release upon cell death [11]. In particular, necrosis rather than apoptosis was assumed to be responsible for the release of sHSP70 [38]. However, cell death accounts only for a minor fraction of sHSP70, and it is mainly released in an active manner [11]. Mambula and Calderwood postulated an endolysosomal route as a mechanism for soluble HSP70 (sHSP70), as the secretion correlated with the lysosomal marker lysosomal-associated membrane protein 1 (LAMP1) and could be inhibited by lysosomotropic compounds [39]. Moreover, they showed that HSP70 could enter lysosomes via ATP-binding cassette (ABC) family transporter proteins [39]. Interestingly, ABC transporters are also expressed on endosomes and exosomes, where one could postulate a possible way for HSP70 loading into exosomes. The secreted chaperone was also found to bind back to the plasma membrane, indicating an alternative route to the lipid raft-mediated pathway for membrane-associated HSP70 [39].

Another way of HSP70 release was demonstrated by Evdonin et al., showing the formation of secretory-like granules upon inhibition of phospholipase C [32]. Interestingly, this secretion could be blocked by brefeldin A, indicating an involvement of the classical secretory pathway [32,40]. This was contradictory to prior studies that demonstrated no inhibition of the secretory pathway by brefeldin A [6,12,15]. However, the authors suggested a time-dependent effect since previous studies evaluated the translocation of HSP70 at least 4 h after inducing stress or treatment with brefeldin A [40]. Therefore, it can be postulated that distinct cells potentially use different mechanisms, possibly depending on the stress level and exposure.

Altogether, it can be concluded that translocation of HSP70 into the extracellular milieu is increased under stress conditions and that several pathways lead to either membrane-, EV-associated, or soluble HSP70 (Figure 1). Still, additional research is needed to further unravel the different mechanisms and their functional consequences.
3. Role of exHSP70: Regulation of Immune Responses

The immune system is a complex network of biological processes protecting us from various pathogens and diseases. It is mainly divided into two groups, the innate immune system, which is defined by a non-specific and rapid response, and the adaptive immune system, which can respond and adapt to specific stress stimuli. A typical immune response can be divided into four phases: (I) Recognition of pathogen- or damage-associated molecular patterns (PAMPs/DAMPs) by innate immune cells resulting in phagocytosis, complement activation, and secretion of pro-inflammatory cytokines. (II) Released cytokines, such as IL-1, IL-12, or TNF-α, then trigger an acute inflammatory response helping to control the infection. (III) Meanwhile, antigen-presenting cells (APCs) activate naïve T-helper cells via their MHC class II and co-stimulatory signal molecules. (IV) Activated T-helper cells subsequently initiate the adaptive immune system, including a cell-mediated and humoral immune response [41].

In the case of inflammation, intracellular HSP70 expression is dramatically increased and exerts cytoprotective functions. This is achieved both through classical chaperone functions, such as refolding and repair of proteins, and by direct inhibition of apopto-
sis [42]. Since excessive apoptosis can lead to severe human inflammatory diseases (HIDs), HSP70 plays a crucial role in balancing the appropriate response to cell stress. However, in cancer, HSP70 is known to be overexpressed, upsetting the balance and increasing proliferation, invasiveness, and resistance of malignant cells [2]. As described in the previous chapter, HSP70 is known to translocate into the extracellular milieu primarily upon stress stimuli. Moreover, exHSP70 was shown to exert pro-inflammatory functions, leading to increased tissue damage, indicating a dual role of HSP70 [43]. In the following section, we provide an overview of the general mechanisms of exHSP70 in immunity and summarize current data of its functions towards immune cells in the tumor microenvironment.

### 3.1. General Mechanisms of Immunomodulation by exHSP70

The role of HSP70 in immunity is still extensively discussed in the literature, and a plethora of distinct functions and mechanisms are described. It is associated with developing an innate and adaptive immune response, formation of memory cells, and termination of the immune response [2].

To exert specific immunomodulatory functions, proteins need to interact with immune cells. Here, membrane-bound and free HSP70 were both shown to bind to different immune cells, including macrophages, dendritic cells, and natural killer (NK) cells [44–46]. Moreover, in the early 2000s, Asea and colleagues demonstrated that exHSP70 specifically binds to monocytes, increasing the pro-inflammatory cytokines TNF-α, IL-6, and IL-1β [47]. This was postulated to be mediated by two distinct pathways: a CD14-dependent and a CD14-independent mechanism, with both being dependent on intracellular calcium. Consequently, exHSP70 binds monocytes, increasing the intracellular calcium flux and resulting in NF-κB-mediated transcription of pro-inflammatory cytokines [47]. Hence, the authors termed HSP70 a “chaperokine” [48]. This finding led to many publications displaying pro-inflammatory cytokine functions of HSP70 [49–51]. In addition to CD14, Toll-like receptors 2 and 4 (TLR2/TLR4) and CD40 were also described to mediate those effects, mainly via NF-κB and the MAPK pathway [49,51,52]. The fact that HSP70 could be released during necrotic cell death and subsequently induce an inflammatory response by TLR and being increasingly expressed in various inflammatory diseases emphasized its role as a DAMP [38,47,51].

However, shortly after the first publication, Gao and Tsan issued their concerns about the pro-inflammatory functions and postulated that endotoxin contamination and not HSP70 itself could trigger those effects [53]. They showed that highly purified recombinant HSP70 could not induce TNF-α in murine macrophages [53]. Moreover, endotoxin-free HSP70 was not able to mature dendritic cells, as described earlier [38,54]. Further studies from different groups supported the theory that most pro-inflammatory functions could be due to contamination [55–58]. Therefore, results obtained using recombinant HSP70, mainly produced in *Escherichia coli* (*E. coli*), need to be interpreted with caution. In addition, studies with purified recombinant proteins are limited since the activity of HSP70-protein complexes is often overlooked.

Fong and co-workers gave another explanation of the contradictory results. They showed that exHSP70 binds to sialic acid-binding immunoglobulin-type lectins (Siglecs), which are membrane proteins expressed on immune cells. In particular, exHSP70 can interact with the anti-inflammatory Siglec-5 as well as the pro-inflammatory Siglec-14. Different expression patterns of Siglecs in specific immune cell populations could therefore explain different inflammatory responses [59].

Interestingly, recent studies introduced another receptor that potentially induces pro-inflammatory functions [60,61]. Here, the authors showed that exHSP70 binds to the receptor for advanced glycation endproducts (RAGE), leading to extracellular signal-regulated kinases (ERK)-dependent activation of NF-κB. Apart from releasing pro-inflammatory cytokines, activated NF-κB also increased RAGE expression, resulting in a positive feedback loop [61].
In contrast, it was also reported that exHSP70 has rather anti-inflammatory than pro-inflammatory functions [62]. Studies showed that highly purified exHSP70 downregulated TNFα and IL-6 production in monocytes [63]. This was explained by upregulation of the heat shock factor 1 (HSF1), subsequently inhibiting NF-κB activation and directly binding the TNFα gene promoter [63,64]. Extracellular HSP70 was also shown to repress LPS-induced cytokines in rats [65]. In addition, in most neurological disorders, the chaperone was described to be primarily anti-inflammatory [66].

The function of HSP70 in the adaptive immune response is less controversial. It is widely accepted that the chaperone plays a significant role in the antigen-presenting process. Firstly, HSP70 can bind antigens either inside or outside of the cell [67]. The complex is then recognized by APCs via the CD91 or scavenger receptors, such as LOX-1 or SREC-1, resulting in endocytosis [68]. Inside of the APCs, HSP70 protects the antigen until it reaches the proteasome. Here, the antigen is released, processed, and transported to MHC class I molecules [69]. This unique cross-presentation finally leads to the activation of CD8+ T-cells. Moreover, the HSP70-antigen complex can be processed in the lysosome leading to the presentation of the antigen on MHC class II molecules, subsequently activating CD4+ T-cells [69]. The presentation itself was shown to be significantly enhanced by the HSP70-antigen complex compared to the antigen alone [70]. Therefore, HSP70 is essential for the transport, uptake, protection, and effective (cross-)presentation of antigens.

Additionally, to the four phases of a typical immune response, the generation of immunological memory is crucial. Generally, the formation of B- and T-memory cells depends on the respective B- and T-cell receptors (BCR/TCR) and the MHC class II antigen complex [41]. In 2005, researchers of the University of Tuebingen showed enhanced activation of CD4+ memory T-cells by HSP70-peptide complexes compared to peptides alone [71]. This activation was shown to be dependent on CD91 and scavenger receptors [72]. Moreover, Wang and colleagues demonstrated a TCR- and MHC class II-independent mechanism of CD4+ memory T-cell formation [73]. Here, stress-induced dendritic cells upregulated intracellular and membrane-associated HSP70, which activates NF-κB via CD40, resulting in increased membrane-bound IL-15 expression. The IL-15 then activates the JAK3 and STAT5 pathway in CD4+ T-cells, upregulating CD40L, which can reactivate the DCs for a positive feedback loop and subsequently lead to the formation of CD4+ memory T-cells [73]. This was the first time researchers could demonstrate the formation of memory cells independent of the antigen. These results were also validated in vivo [74].

The last step of the immune response is the termination, which is vital to prevent tissue damage by excessive inflammation [75]. Overexpression of HSP70 on the surface of immune cells serves as a regulator for the termination by displaying a “death signal” [76]. HSP70 is hereby recognized by γδT killer cells, which subsequently terminate the cells [76]. Moreover, HSP70 was shown to prime γδT killer cells, leading to higher proliferation and killing [77]. This priming could be dependent on TLRs [78].

All in all, HSP70 is crucially involved in many aspects of immunity, including the development of the innate and adaptive immune response, the formation of memory cells, and the termination of the immune response. Hereby, the chaperone exhibit either pro- or anti-inflammatory functions, potentially depending on its location, cell type, and expression level. Several receptors are known to interact with exHSP70, such as CD40, TLR2, TLR4, CD14, RAGE, CD91, as well as different scavenger receptors, primarily exhibiting their function via the NF-κB or MAPK pathway.

3.2. The Role of exHSP70 in Immunomodulation of Cancer

The communication of cancer cells and immune cells is a crucial step in cancer progression. Therefore, understanding the mechanisms and consequences of the interaction is essential. A potential key player of the crosstalk in the tumor microenvironment may be HSP70, which is overexpressed in cancer compared to normal tissue [2,79–82]. The expression was shown to be correlated to tumor grade, therapy resistance, and worse overall survival [80–85]. In particular, HSP70 can inhibit the intrinsic and extrinsic apoptotic pathway.
and block oncogene-induced senescence, resulting in therapy resistance [2]. The chaperone was also reported to be translocated into the extracellular milieu in cancer, including as a membrane-bound or as an exosome secreted form [82,83,86–89]. Recently, Finkernagel and colleagues were able to identify HSP70 as a major constituent of ovarian cancer EVs and demonstrated a significant correlation of exHSP70 with patient survival [88]. Moreover, in a prospective clinical study of breast and lung cancer, exosomal HSP70 was correlated to metastasis and disease status. Here, the authors suggested HSP70-positive exosomes as a potential biomarker to predict tumor responses and clinical outcomes [82].

One candidate of the pro-tumorigenic effects of exHSP70 could be TLR4 and the subsequent PI3K/Akt pathway engagement. It is described that the pathway leads to IL-10 and galectin-1 production, resulting in an increase of matrix-metalloproteases 2 and 9 (MMP-9/MMP-2), finally enhancing tumor migration [90]. The induction of MMP-2 and MMP-9 by exosomal HSP70 was already reported in mesoangiblasts, where initiation occurred via TLR4 and CD91 in an autocrine fashion [91]. In addition, MMP-9 induction was also reported in monocytes. Extracellular HSP70 stimulated NF-κB and activating protein-1 (AP-1), enabling MMP-9 expression [92]. Interestingly, HSP70 was also shown to increase its own expression via the TLR4 by inactivating glycogen synthase kinase-3β (GSK-3β) via Akt signaling. Inactivation of GSK-3β then stimulated HSF1, finally inducing intracellular HSP70 [93]. It was also reported that tumor-derived exosomal HSP70 activated myeloid-derived suppressor cells (MDSC), enhancing tumor growth [94]. This is due to TLR2 activation and subsequent MyD88-dependent phosphorylation of the signal transducer and activator of transcription 3 (STAT3) [94,95]. STAT3 is known to be critically involved in tumor progression and generation of an immunosuppressive and therefore pro-tumorigenic environment [96,97]. Moreover, activation of TLR2 by exosomal HSP70 led to upregulation of IL-6, iNos, and Arg-1 [95]. Thereby, iNos enhances nitric oxide production, whereas Arg-1 leads to arginine depletion, both inhibiting T-cell proliferation and function [98,99]. MyD88-independent activation of TLR4 by exHSP70 was also described to facilitate cancer growth, potentially through the TRIF pathway [100].

The interaction of exHSP70 with TLR 2/4 was further demonstrated to activate neutrophils [88]. Klink and co-workers showed that activation of those receptors led to the production of reactive oxygen species (ROS) and the release of IL-8. This is associated with cancer progression since ROS can stimulate the expression of vascular endothelial growth factor (VEGF) and activate MMPs, thus enhancing tumor angiogenesis and metastasis [88,101]. Moreover, exHSP70-TLR2 interaction also leads to activation and pro-inflammatory cytokine production in neutrophils [102].

Additionally, the TLR4 pathway was suggested to play a role in chemotherapy resistance [103]. In ovarian cancer, TLR4 activation resulted in MyD88-dependent nuclear localization of NFκB, upregulating the production of IL-6 as well as the chemokines MCP-1 and GRO-α, which are all associated with tumor progression. Furthermore, the Akt pathway was activated, followed by enhanced expression of the anti-apoptotic protein XIAP, thus exhibiting resistance to chemotherapy [103,104]. In accordance, a recent study showed that transfer of exHSP70 via small EVs resulted in therapy resistance of breast cancer by increasing ROS production [105].

Epithelial to mesenchymal transition (EMT) is believed to be a key step of cancer cells to enable tumor invasion and metastasis. Li and colleagues showed that treating cells with tumor-derived exHSP70 resulted in the decrease of E-cadherin and the increase of α-SMA and, therefore, in the induction of EMT [106]. This was mediated by TLR2/4 and subsequent activation of the JNK1/2 and MAPK pathways [107].

Another target of exHSP70 is the receptor RAGE, which was shown to result in a pro-inflammatory response via ERK-dependent NF-κB activation [61]. Interestingly, RAGE was also found to be overexpressed in cancer, where it was correlated to tumor size and cancer stage [108,109]. Additionally, RAGE is expressed on immune cells, such as monocytes or macrophages, further extending possible targets for exHSP70 [110]. It is also described that
RAGE interacts with TLR4 and that this crosstalk leads to MyD88-dependent activation of NF-κB \([110,111]\) (Figure 2).
γ. The cytokines then stimulate CD4+ T-cells to secrete IL-2, finally activating NK cells. Moreover, CD8+ T-cells are also activated by this mechanism and can kill tumor cells via FasL/Fas interaction [116]. Interestingly, FasL can trigger the secretion of an HSP70-Tag7 complex in T-cells. This complex further induces tumor cell lysis via the tumor necrosis factor receptor 1 (TNFR1) [117,118].

Dendritic cells can also be stimulated by binding to the TLR4. Activation of MyD88- and TRIF-dependent pathways results in the production of chemokines, such as CXCL10 or CCL5, engaging immune cells and inducing anti-tumor immunity [119].

Furthermore, exHSP70 was reported to inhibit the conversion of monocytes to a pro-tumor phenotype, which is potentially due to a diminished expression of pro-tumor cytokines, such as IL-10 and MCP-1 [120].

Finally, as described in the previous chapter, exHSP70 can induce an adaptive immune response by (cross-) presentation of antigens on MHC class I or II molecules. In particular, HSP70-antigen complexes are endocytosed by APCs after binding to CD91 or other scavenger receptors, where the antigen is processed and presented to T-cells [69].

Increasing evidence emphasizes exHSP70 as an important player in mediating immune responses in cancer by either exerting pro- or anti-tumorigenic functions. However, there is still much unknown or controversially described; thus, specific functions and their associated mechanism urgently need to be investigated.
4. Therapeutic Potential of exHSP70

Since intracellular HSP70 is upregulated in cancer and elicits anti-apoptotic functions, it represents an important target for developing new therapeutics. Typical inhibitors are small molecules targeting various aspects of the HSP70 machinery [121]. These include ATPase and complex inhibitors as well as nucleotide-binding domain (NBD)- or substrate-binding domain (SDB)-targeting inhibitors [121]. Apart from small molecule inhibitors, Minnelide, a Triptolide derivative, has been shown to effectively downregulate HSP70 by inducing the miRNA miR-142–3p [122,123]. Additionally, Minnelide is currently tested in several phase I and II studies, including pancreatic cancer and acute myeloid leukemia [2]. Although targeting iHSP70 and therefore altering its expression or function also affects exHSP70, the linkages and consequences are not well understood.

4.1. HSP70 Antibody

The fact that mHSP70 is uniquely expressed on cancer cells compared to normal tissue makes it an excellent therapeutic target [124,125]. Gabrielle Multhoff’s group developed a specific IgG antibody directed against the exposed region of mHSP70 by immunizing mice with a 14-mer peptide (TKDNLLGRFELSG, known as TKD) that encompasses the amino acids 450–463 of the chaperone [126,127]. This antibody, known as cmHsp70.1 mAb, was shown to bind specifically to mHSP70 in vitro and in vivo [127]. In addition, antibody-dependent cell-mediated cytotoxicity (ADCC), induced by the Fc-region of the antibody, was shown to significantly inhibit tumor growth in a preclinical study in mice [126]. However, IgG antibodies are inefficient in inducing ADCC, primarily via neutrophils, due to the binding of several inhibitory Fc-receptors [128]. Therefore, IgA antibodies should be considered an alternative since they efficiently induce ADCC by binding to the Fcα-receptor (CD89) on neutrophils, monocytes, and macrophages [129]. Furthermore, IgA antibodies do not activate the classical complement pathway, consequently being rather anti-inflammatory than IgG antibodies [130]. The ability to oligomerize enables IgA to bind and crosslink several Fc-receptors, which was reported to release the chemottractant LTB4, engaging neutrophils for tumor cell killing [131]. Disadvantages, such as the short serum half-life, could be overcome by antibody engineering [132].

The antibody cmHSP70.1 was also reported to be efficiently endocytosed by tumor cells, offering a specific route for targeted therapy [127]. Therefore, superparamagnetic iron oxide nanoparticles (SPIONs), a specific group of magnetic nanoparticles (MNPs), were decorated with the antibody [133,134]. The results showed an increase in retention of the particles in a glioma model in vivo [133]. Generally, MNPs can be used for diagnosis via magnetic resonance imaging or exploited for therapy by applying an alternate magnetic field (AMF) [135]. The AMF results in the spinning of iron particles, generating heat and killing the tumor by hyperthermia [135]. Interestingly, inducing ionizing radiation after injecting the particles significantly increased the retention of the particles in the tumor [134]. This is in line with the findings that radiation increases mHSP70 in tumor cells [136].

An alternative to MNPs are gold nanoparticles (AuNPs), which have a good biocompatibility and are easy to synthesize, although their costs of synthesizing are quite high [136]. They can be used for several applications, including delivering different compounds and photothermal or photodynamic therapy [136]. Recently, AuNPs coated with cmHsp70.1 mAb were shown to enable computed tomography of tumors in a preclinical study [137].

Using extracellular vesicles as specific carriers of drugs is another promising approach. Since EVs are naturally occurring vesicles, side-effects of the carrier should be minimal. Moreover, EVs could be engineered to express HSP70 and specifically target tumor cells while carrying distinct molecules for tumor cell killing. In 2010, Xie and colleagues demonstrated that mHSP70 engineered exosomes efficiently induced DC maturation, which increased T- and NK cell-dependent tumor killing [138]. Other reports showed successful loading of the chemotherapeutic paclitaxel into exosomes, resulting in tumor growth inhibition [139,140].
4.2. HSP70 Peptides

Since exHSP70 was shown to stimulate immune cells for tumor cell killing, the 14mer-peptide, which was used to generate the antibody, was also investigated as a therapeutic option. In the early 2000s, Multhoff and co-workers reported TKD as a recognition structure for NK cells and showed that it stimulated the proliferative and cytolytic activity [113]. Shortly after, TKD was successfully studied in a phase I trial, where NK cells were stimulated ex vivo, together with low doses of IL-2 [141]. This was supported by a recent phase II trial, where the peptide showed promising results in non-small cell lung cancer [142]. Moreover, together with the inhibition of the programmed cell death protein 1 (PD-1), a prolongation in patient survival was reported in several phase II trials of glioblastoma and lung cancer [143,144].

Another group developed a small peptide targeting the SBD of HSP70. The A8 peptide aptamer showed a decrease in MDSC and inhibited tumor progression in vivo [94]. This was due to a higher affinity of mHSP70 to A8 compared to the TLR2, thus blocking HSP70/TLR2 interaction. Therefore, A8 effectively blocked the exosome-mediated activation of MDSCs. Moreover, MDSC proliferation was also hampered since TLR2-dependent production of IL-6 via pSTAT3 was blocked. Interestingly, treating mice with cisplatin or 5-Fluorouracil led to increased HSP70-bearing exosomes, enhancing activation of MDSCs [94].

Recently, Lin and colleagues demonstrated that a 72 bp long peptide (Tx-01) could suppress ovarian cancer migration and growth in vivo [145]. They showed that Tx-01 is internalized by endo- or pinocytosis, where it binds to iHSP70, which consequently blocks the interaction of HSP70 with the Notch1 intracellular domain (NICD). This hampers the nuclear localization of HSP70, decreasing tumor invasion and migration. In addition, Tx-01 can also bind to mHSP70 leading to a rapid internalization, where it subsequently blocks the translocation of HSP70. Furthermore, the binding of Tx-01 to mHSP70 could be used as a prognostic marker in serous ovarian carcinoma [145].

In addition to peptides and antibodies, granzyme B has been reported to bind to mHSP70, leading to internalization and subsequent apoptosis of the cells [44]. Moreover, the enzyme showed significant tumor suppression of HSP70-positive colon carcinoma in vivo [31]. Recently, granzyme B-tagged SPIONs were developed, demonstrating increased survival of mice with glioblastoma or late-stage lung cancer [146]. Magnetic targeting further enhanced the localization of the SPIONs within the tumor. In addition, the nanoparticles could be used to image HSP70-positive tumors by magnetic resonance imaging [146].

4.3. HSP70 Vaccines

Since exHSP70 was shown to trigger T-cell responses, using it as a vaccine is another potential therapy approach. In particular, tumors are stimulated to secrete HSP70 (and antigens), which can subsequently be purified. HSP70-peptide complexes are then used as vaccines, where they mediate cross-presentation of the antigen in DCs, finally activating CD8+ T-cells [147]. This approach was already investigated in the early 2000s, where researchers showed inhibition of tumor growth in a prostate cancer mouse model [147]. Moreover, using HSP70-peptide complexes from the fusion of DCs and tumor cells significantly enhanced DC maturation and T-cell responses [148].

In summary, targeting exHSP70 represents an interesting theranostic approach. Since exHSP70 is uniquely expressed in tumors and not in normal cells, targeting can be used for both imaging and therapeutic approaches. Various strategies are being investigated, including peptides, antibodies, and enzymes, that bind either directly to HSP70 on tumor cells/EVs or target receptors on immune cells. The latter would mimic a vaccination and lead to activation and engagement of immune cells for tumor cell killing. Finally, vehicles such as nanoparticles or EVs can further enhance tumor imaging or treatment by carrying cytotoxic compounds. HSP70 may also be linked as a chaperone to DNA vaccines to enhance immunogenicity in humans [149]. In this study HSP70 was linked to the HPV16 E7 sequence to facilitate uptake by antigen-presenting cells and antigen presentation.
HPVE7-specific T-cell responses were generally of low frequency but increased in subjects in the second and third cohorts. Tumor regression was reported in 3 out of 9 patients; however, significance of these results needs to be confirmed in further studies.

5. Conclusions

Cellular stress leads to a multitude of molecular responses, guarding cells from damages. One specific response is the upregulation of the inducible HSP70, subsequently protecting cells via chaperone activities or inhibiting apoptosis. However, in cancer, HSP70 is overexpressed, leading to tumor progression and therapy resistance. Moreover, the chaperone is translocated to the extracellular milieu by several pathways, resulting in membrane-bound, EV-associated, or soluble HSP70. Hereby, exHSP70 can interact with immune cells of the tumor microenvironment, where it operates as a double-edged sword. By targeting different receptors on immune cells, it is able to either trigger pro- or anti-tumorigenic responses. Pro-tumorigenic responses include stimulating neutrophils or monocytes to secrete pro-inflammatory cytokines or activating MDSC, which results in reduced T-cell activity. In contrast, anti-tumorigenic responses comprise activation of NK cells, either directly or indirectly via DCs, and activation of T-cell by stimulating monocytes. Moreover, mediating (cross-)presentation of antigens on MHC class I or II molecules also activates the adaptive immune response for tumor cell killing. Since exHSP70 is uniquely expressed in cancer compared to normal tissue, it is a valuable therapeutic target. Therapies can include targeting exHSP70 or its receptors on tumor-, immune cells or EVs. Moreover, HSP70-antigen complexes can be used to prime immune cells for an effective anti-tumor response.

Although it is widely believed that exHSP70 can trigger opposing effects, much is still unknown or critically debated. For instance, cytokine activities of exHSP70 were questioned since this might be a result of endotoxin contamination. Moreover, the actions of HSP70-protein complexes are often overlooked but, depending on the complex, could trigger different responses. Altogether, exHSP70 can emerge as a crucial player in cancer therapy; however, a better understanding of its function is essential. Therefore, more research regarding specific mechanisms as well as novel therapeutic strategies are needed.

**Funding:** M.L. and E.P.v.S. are funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)-GRK 2573/1.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Acknowledgments:** We thank Christian Preußer and Viviane Ponath (Phillips University Marburg) for their comments on the manuscript.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Rosenzweig, R.; Nillegoda, N.B.; Mayer, M.P.; Bukau, B. The Hsp70 Chaperone Network. *Nat. Rev. Mol. Cell Biol.* 2019, 20, 665–680. [CrossRef] [PubMed]
2. Albakova, Z.; Armeev, G.A.; Kanevskiy, L.M.; Kovalenko, E.I.; Sapozhnikov, A.M. HSP70 Multi-Functionality in Cancer. *Cells* 2020, 9, 587. [CrossRef] [PubMed]
3. Van Niel, G.; D’Angelo, G.; Raposo, G. Shedding Light on the Cell Biology of Extracellular Vesicles. *Nat. Rev. Mol. Cell Biol.* 2018, 19, 213–228. [CrossRef] [PubMed]
4. Kalluri, R.; LeBleu, V.S. The Biology, Function, and Biomedical Applications of Exosomes. *Science* 2020, 367. [CrossRef]
5. Liu, Y.; Wang, Y.; Lv, Q.; Li, X. Exosomes: From Garbage Bins to Translational Medicine. *Int. J. Pharm.* 2020, 583, 119333. [CrossRef] [PubMed]
6. Lancaster, G.I.; Febbraio, M.A. Exosome-Dependent Trafficking of HSP70: A Novel Secretory Pathway for Cellular Stress Proteins. *J. Biol. Chem.* 2005, 280, 23349–23355. [CrossRef] [PubMed]
7. Vega, V.L.; Rodriguez-Silva, M.; Frey, T.; Gehrmann, M.; Diaz, J.C.; Steinem, C.; Multhoff, G.; Arispe, N.; Maio, A.D. Hsp70 Translocates into the Plasma Membrane after Stress and Is Released into the Extracellular Environment in a Membrane-Associated Form That Activates Macrophages. *J. Immunol.* **2008**, *180*, 4299–4307. [CrossRef] [PubMed]

8. Multhoff, G.; Botzler, C.; Wiesnet, M.; Müller, E.; Meier, T.; Wilmanns, W.; Issels, R.D. A Stress-Inducible 72-KDa Heat-Shock Protein (HSP72) Is Expressed on the Surface of Human Tumor Cells, but Not on Normal Cells. *Int. J. Cancer* **1995**, *61*, 272–279. [CrossRef]

9. Pockley, A.G.; Shepherd, J.; Corton, J.M. Detection of Heat Shock Protein 70 (Hsp70) and Anti-Hsp70 Antibodies in the Serum of Normal Individuals. *Immunol. Invest.* **1997**, *26*, 367–377. [CrossRef]

10. Owji, H.; Nezafat, N.; Negahdaripour, M.; Hajiebrahimi, A.; Ghasemi, Y. A Comprehensive Review of Signal Peptides: Structure, Roles, and Applications. *Eur. J. Cell Biol.* **2018**, *97*, 422–441. [CrossRef] [PubMed]

11. Mambula, S.S.; Stevenson, M.A.; Ogawa, K.; Calderwood, S.K. Mechanisms for Hsp70 Secretion: Crossing Membranes without a Leader. *Methods* **2007**, *43*, 168–175. [CrossRef]

12. Broquet, A.H.; Thomas, G.; Masliah, J.; Trugnan, G.; Bachelet, M. Expression of the Molecular Chaperone Hsp70 in Detergent-Resistant Microdomains Correlates with Its Membrane Delivery and Release. *J. Biol. Chem.* **2003**, *278*, 21601–21606. [CrossRef]

13. Nylander, S.; Kalies, I. Brefeldin A, but Not Monensin, Completely Blocks CD69 Expression on Mouse Lymphocytes: Efficacy of Inhibitors of Protein Secretion in Protocols for Intracellular Cytokine Staining by Flow Cytometry. *J. Immunol. Methods* **1999**, *224*, 69–76. [CrossRef]

14. Sezgin, E.; Levental, I.; Mayor, S.; Egelman, C. The Mystery of Membrane Organization: Composition, Regulation and Roles of Lipid Rafts. *Nat. Rev. Mol. Cell Biol.* **2017**, *18*, 361–374. [CrossRef]

15. Hunter-Lavin, C.; Davies, E.L.; Bacelar, M.F.F.V.G.; Marshall, M.J.; Andrew, S.M.; Williams, J.H.H. Hsp70 Release from Peripheral Blood Mononuclear Cells. *Biochem. Biophys. Res. Commun.* **2004**, *324*, 511–517. [CrossRef]

16. Gehrmann, M.; Liebisch, G.; Schmitz, G.; Anderson, R.; Steinem, C.; De Maio, A.; Pockley, G.; Multhoff, G. Tumor-Specific Hsp70 Plasma Membrane Localization Is Enabled by the Glycosphingolipid Gb3. *PLoS ONE* **2008**, *3*, e1925. [CrossRef]

17. Smulders, L.; Daniels, A.J.; Plescia, C.B.; Berger, D.; Stahelin, R.V.; Nikolaidis, N. Characterization of the Relationship between the Chaperone and Lipid-Binding Functions of the 70-KDa Heat-Shock Protein, HspA1A. *Int. J. Mol. Sci.* **2020**, *21*, 5995. [CrossRef] [PubMed]

18. McCallister, C.; Kdeiss, B.; Nikolaidis, N. Biochemical Characterization of the Interaction between HspA1A and Phospholipids. *Cell Stress Chaperones* **2016**, *21*, 41–53. [CrossRef] [PubMed]

19. Schilling, D.; Gehrmann, M.; Steinem, C.; De Maio, A.; Pockley, A.G.; Abend, M.; Molls, M.; Multhoff, G. Binding of Heat Shock Protein 70 to Extracellular Phosphatidylserine Promotes Killing of Normoxic and Hypoxic Tumor Cells. *FASEB J.* **2009**, *23*, 2467–2477. [CrossRef] [PubMed]

20. Alder, G.M.; Austen, B.M.; Bashford, C.L.; Mehlert, A.; Pasternak, C.A. Heat Shock Proteins Induce Pores in Membranes. *Biosci. Rep.* **1990**, *10*, 509–518. [CrossRef]

21. Bilog, A.D.; Smulders, L.; Oliverio, R.; Labanieh, C.; Zapanta, J.; Stahelin, R.V.; Nikolaidis, N. Membrane Localization of HspA1A, a Stress Inducible 70-KDa Heat-Shock Protein, Depends on Its Interaction with Intracellular Phosphatidylserine. *Biomolecules* **2019**, *9*, 152. [CrossRef]

22. Gastpar, R.; Gehrmann, M.; Bausero, M.A.; Asea, A.; Gross, C.; Schroeder, J.A.; Multhoff, G. Heat Shock Protein 70 Surface-Positive Tumor Exosomes Stimulate Migratory and Cytolytic Activity of Natural Killer Cells. *Cancer Res.* **2005**, *65*, 5238–5247. [CrossRef]

23. Clayton, A.; Turkes, A.; Navabi, H.; Mason, M.D.; Tabi, Z. Induction of Heat Shock Proteins in B-Cell Exosomes. *J. Cell Sci.* **2005**, *118*, 3631–3638. [CrossRef]

24. Takeuchi, T.; Suzuki, M.; Fujikake, N.; Popiel, H.A.; Kikuchi, H.; Futaki, S.; Wada, K.; Nagai, Y. Intercellular Chaperone Transmission via Exosomes Contributes to Maintenance of Protein Homeostasis at the Organismal Level. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, E2497–E2506. [CrossRef] [PubMed]

25. Smith, V.L.; Jackson, L.; Scorey, J.S. Ubiquitination as a Mechanism To Transport Soluble Mycobacterial and Eukaryotic Proteins to Exosomes. *J. Immunol.* **2015**, *195*, 2722–2730. [CrossRef] [PubMed]

26. Moreno-Gonzalo, O.; Villarroya-Beltri, C.; Sánchez-Madrid, F. Post-Translational Modifications of Exosomal Proteins. *Front. Immunol.* **2014**, *5*, 383. [CrossRef] [PubMed]

27. Kattmaz, D.J.; Odorizzi, G.; Emr, S.D. Receptor Downregulation and Multivesicular-Body Sorting. *Nat. Rev. Mol. Cell Biol.* **2002**, *3*, 893–905. [CrossRef]

28. Nikita; Porter, C.M.; Truman, A.W.; Truttman, M.C. Post-translational modifications of Hsp70 family proteins: Expanding the chaperone code. *J. Biol. Chem.* **2020**, *295*, 10689–10708. [CrossRef]

29. Soss, S.E.; Rose, K.L.; Hill, S.; Jouan, S.; Chazin, W.J. Biochemical and Proteomic Analysis of Ubiquitination of Hsc70 and Hsp70 by the E3 Ligase CHIP. *PloS ONE* **2015**, *10*, e0128240. [CrossRef]

30. Quintana-Gallardo, L.; Martín-Benito, J.; Marcilla, M.; Espadas, G.; Sabido, E.; Valpuesta, J.M. The Cochaperone CHIP Marks Hsp70- and Hsp90-Bound Substrates for Degradation through a Very Flexible Mechanism. *Sci. Rep.* **2019**, *9*, 5102. [CrossRef]

31. Jiang, J.; Ballinger, C.A.; Wu, Y.; Dai, Q.; Cyr, D.M.; Höhfeld, J.; Patterson, C. CHIP Is a U-Box-Dependent E3 Ubiquitin Ligase: Identification of Hsc70 as a Target for Ubiquitination. *J. Biol. Chem.* **2001**, *276*, 42938–42944. [CrossRef]

32. Evdonin, A.L.; Guzhova, I.V.; Margulis, B.A.; Medvedeva, N.D. Phospholipase C Inhibitor, U73122, Stimulates Release of Hsp-70 Stress Protein from A431 Human Carcinoma Cells. *Cancer Cell Int.* **2004**, *4*, 2. [CrossRef] [PubMed]
33. Li, Z.; Zhuang, M.; Zhang, L.; Zheng, X.; Yang, P.; Li, Z. Acetylation Modification Regulates GRP78 Secretion in Colon Cancer Cells. *Sci. Rep.* **2016**, *6*, 30406. [CrossRef] [PubMed]

34. Yang, Y.; Fiskus, W.; Yong, B.; Atadja, P.; Takahashi, Y.; Pandita, T.K.; Wang, H.-G.; Bhalla, K.N. Acetylated Hsp70 and KAP1-Mediated Vps34 SUMOylation Is Required for Autophagosomal Creation in Autophagy. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 6841–6846. [CrossRef] [PubMed]

35. Fang, Y.; Wu, N.; Gan, X.; Yan, W.; Morrell, J.C.; Gould, S.J. Higher-Order Oligomerization Targets Plasma Membrane Proteins and HIV Gag to Exosomes. *PLoS Biol.* **2007**, *5*, e188. [CrossRef] [PubMed]

36. Nimmervoll, B.; Chctehglova, L.A.; Juhasz, K.; Cremades, N.; Aprile, F.A.; Sonnleitner, A.; Hinterdorfer, P.; Vigh, L.; Preiner, J.; Balogi, Z. Cell Surface Localised Hsp70 Is a Cancer Specific Regulator of Clathrin-Independent Endocytosis. *FEBS Lett.* **2015**, *589*, 2747–2753. [PubMed]

37. Takakuwa, J.E.; Nitta; Knighton, L.E.; Truman, A.W. Oligomerization of Hsp70: Current Perspectives on Regulation and Function. *Front. Mol. Biosci.* **2019**, *6*, 81. [CrossRef] [PubMed]

38. Basu, S.; Binder, R.J.; Suto, R.; Anderson, K.M.; Srivastava, P.K. Necrotic but Not Apoptotic Cell Death Releases Heat Shock Proteins, Which Deliver a Partial Maturation Signal to Dendritic Cells and Activate the NF-KB Pathway. *Int. Immunol.* **2000**, *12*, 1539–1546. [CrossRef]

39. Mambula, S.S.; Calderwood, S.K. Heat Shock Protein 70 Is Secreted from Tumor Cells by a Nonclassical Pathway Involving Lysosomal Endosomes. *J. Immunol.* **2006**, *177*, 7849–7857. [CrossRef]

40. Evdonin, A.L.; Martynova, M.G.; Bystrova, O.A.; Guzhova, I.V.; Margulis, B.A.; Medvedeva, N.D. The Release of Hsp70 from A431 Carcinoma Cells Is Mediated by Secretory-like Granules. *Eur. J. Cell Biol.* **2006**, *85*, 443–455. [CrossRef] [PubMed]

41. Chaplin, D.D. Overview of the Immune Response. *J. Allergy Clin. Immunol.* **2007**, *113*, S3–S23. [CrossRef] [PubMed]

42. Ikwegbue, P.C.; Masamba, P.; Oyinloye, B.E.; Kappo, A.P. Roles of Heat Shock Proteins in Apoptosis, Oxidative Stress, Human Inflammatory Diseases, and Cancer. *Pharmaceuticals* **2017**, *11*, 2. [CrossRef] [PubMed]

43. Joly, A.-L.; Wettstein, G.; Mignot, G.; Ghiringhelli, F.; Garrido, C. Dual Role of Heat Shock Proteins as Regulators of Apoptosis and Innate Immunity. *J. Innate Immun.* **2010**, *2*, 238–247. [CrossRef]

44. Gross, C.; Koelch, W.; DeMaio, A.; Arispe, N.; Multhoff, G. Cell Surface-Bound Heat Shock Protein 70 (Hsp70) Mediates Perforin-Independent Apoptosis by Specific Binding and Uptake of Granzyme B. *J. Biol. Chem.* **2003**, *278*, 41173–41181. [CrossRef] [PubMed]

45. Asea, A.; Kraeft, S.-K.; Stevenson, M.A.; Chen, L.B.; Finberg, R.W.; Koo, G.C.; Calderwood, S.K. HSP70 Stimulates Cytokine Production through a CD14-Dependent Pathway, Demonstrating Its Dual Role as a Chaperone and Cytokine. *Nat. Med.* **2000**, *6*, 435–442. [CrossRef] [PubMed]

46. Stocki, P.; Dickinson, A.M. The Immunosuppressive Activity of Heat Shock Protein 70. *Autoimmune Dis.* **2007**, *5*, 158–169. [CrossRef] [PubMed]

47. Takakuwa, J.E.; Nittka; Knighton, L.E.; Truman, A.W. Oligomerization of Hsp70: Current Perspectives on Regulation and Function. *Front. Mol. Biosci.* **2019**, *6*, 81. [CrossRef] [PubMed]

48. Basu, S.; Binder, R.J.; Suto, R.; Anderson, K.M.; Srivastava, P.K. Necrotic but Not Apoptotic Cell Death Releases Heat Shock Proteins, Which Deliver a Partial Maturation Signal to Dendritic Cells and Activate the NF-KB Pathway. *Int. Immunol.* **2000**, *12*, 1539–1546. [CrossRef]

49. Mambula, S.S.; Calderwood, S.K. Heat Shock Protein 70 Is Secreted from Tumor Cells by a Nonclassical Pathway Involving Lysosomal Endosomes. *J. Immunol.* **2006**, *177*, 7849–7857. [CrossRef]

50. Evdonin, A.L.; Martynova, M.G.; Bystrova, O.A.; Guzhova, I.V.; Margulis, B.A.; Medvedeva, N.D. The Release of Hsp70 from A431 Carcinoma Cells Is Mediated by Secretory-like Granules. *Eur. J. Cell Biol.* **2006**, *85*, 443–455. [CrossRef] [PubMed]

51. Chaplin, D.D. Overview of the Immune Response. *J. Allergy Clin. Immunol.* **2010**, *113*, S3–S23. [CrossRef] [PubMed]

52. Ikwegbue, P.C.; Masamba, P.; Oyinloye, B.E.; Kappo, A.P. Roles of Heat Shock Proteins in Apoptosis, Oxidative Stress, Human Inflammatory Diseases, and Cancer. *Pharmaceuticals* **2017**, *11*, 2. [CrossRef] [PubMed]

53. Joly, A.-L.; Wettstein, G.; Mignot, G.; Ghiringhelli, F.; Garrido, C. Dual Role of Heat Shock Proteins as Regulators of Apoptosis and Innate Immunity. *J. Innate Immun.* **2010**, *2*, 238–247. [CrossRef]

54. Gross, C.; Koelch, W.; DeMaio, A.; Arispe, N.; Multhoff, G. Cell Surface-Bound Heat Shock Protein 70 (Hsp70) Mediates Perforin-Independent Apoptosis by Specific Binding and Uptake of Granzyme B. *J. Biol. Chem.* **2003**, *278*, 41173–41181. [CrossRef] [PubMed]

55. Asea, A.; Kraeft, S.-K.; Stevenson, M.A.; Chen, L.B.; Finberg, R.W.; Koo, G.C.; Calderwood, S.K. HSP70 Stimulates Cytokine Production through a CD14-Dependent Pathway, Demonstrating Its Dual Role as a Chaperone and Cytokine. *Nat. Med.* **2000**, *6*, 435–442. [CrossRef] [PubMed]

56. Stocki, P.; Dickinson, A.M. The Immunosuppressive Activity of Heat Shock Protein 70. *Autoimmune Dis.* **2007**, *5*, 158–169. [CrossRef] [PubMed]

57. Takakuwa, J.E.; Nittka; Knighton, L.E.; Truman, A.W. Oligomerization of Hsp70: Current Perspectives on Regulation and Function. *Front. Mol. Biosci.* **2019**, *6*, 81. [CrossRef] [PubMed]

58. Basu, S.; Binder, R.J.; Suto, R.; Anderson, K.M.; Srivastava, P.K. Necrotic but Not Apoptotic Cell Death Releases Heat Shock Proteins, Which Deliver a Partial Maturation Signal to Dendritic Cells and Activate the NF-KB Pathway. *Int. Immunol.* **2000**, *12*, 1539–1546. [CrossRef]
60. Grunwald, M.S.; Ligabue-Braun, R.; Souza, C.S.; Heimfarth, L.; Verli, H.; Gelain, D.P.; Moreira, J.C.F. Putative Model for Heat Shock Protein 70 Complexation with Receptor of Advanced Glycation End Products through Fluorescence Proximity Assays and Normal Mode Analyses. *Cell Stress Chaperones* 2017, 22, 99–111. [CrossRef] [PubMed]

61. Somersni, N.; Brum, P.O.; de Miranda Ramos, V.; Gasparotto, J.; Zanotto-Filho, A.; Rostirolla, D.C.; da Silva Morrone, M.; Moreira, J.C.F.; Pêns Gelain, D. Extracellular HSP70 Activates ERK1/2, NF-κB and Pro-Inflammatory Gene Transcription Through Binding with RAGE in AS49 A549 Human Lung Cancer Cells. *Cell Physiol. Biochem.* 2017, 42, 2507–2522. [CrossRef]

62. Broere, F.; van der Zee, R.; van Eden, W. Heat Shock Proteins Are No DAMPS, Rather “DAMPers”. *Nat. Rev. Immunol.* 2011, 11, 565. [CrossRef]

63. Ferat-Osorio, E.; Sánchez-Anaya, A.; Gutiérrez-Mendoza, M.; Boscó-Gárate, I.; Wong-Baeza, I.; Pastelin-Palacios, R.; Pedraza-Alva, G.; Bonifaz, L.C.; Cortés-Reynosa, P.; Pérez-Salazar, E.; et al. Heat Shock Protein 70 Down-Regulates the Production of Toll-like Receptor-Induced pro-Inflammatory Cytokines by a Heat Shock Factor-1/Constitutive Heat Shock Element-Binding Factor-Dependent Mechanism. *J. Inflamm.* 2014, 11, 19. [CrossRef]

64. Song, M.; Pinsky, M.R.; Kellum, J.A. Heat Shock Factor 1 Inhibits Nuclear Factor-KappaB Nuclear Binding Activity during Endotoxin Tolerance and Heat Shock. *J. Crit. Care* 2008, 23, 406–415. [CrossRef] [PubMed]

65. Dokladny, K.; Lobb, R.; Wharton, W.; Ma, T.Y.; Moseley, P.L. LPS-Induced Cytokine Levels Are Repressed by Elevated Expression of HSP70 in Rats: Possible Role of NF-κB Signaling. *Cell Stress Chaperones* 2010, 15, 153–163. [CrossRef] [PubMed]

66. Alberti, G.; Paladino, L.; Vitale, A.M.; Caruso Bavisotto, C.; Conway de Macario, E.; Campanella, C.; Macario, A.J.L.; Marino Gammazza, A. Functions and Therapeutic Potential of Extracellular Hsp60, Hsp70, and Hsp90 in Neuroinflammatory Disorders. *Appl. Sci.* 2021, 11, 736. [CrossRef]

67. Noessner, E.; Gastpar, R.; Milani, V.; Brandl, A.; Hutzler, P.J.S.; Kuppner, M.C.; Roos, M.; Kremmer, E.; Asea, A.; Calderwood, S.K.; et al. Tumor-Derived Heat Shock Protein 70 Peptide Complexes Are Cross-Presented by Human Dendritic Cells. *J. Immunol.* 2002, 169, 5424–5432. [CrossRef] [PubMed]

68. Li, Z.; Menoret, A.; Srivastava, P. Roles of Heat-Shock Proteins in Antigen Presentation and Cross-Presentation. *Curr. Opin. Immunol.* 2002, 14, 45–51. [CrossRef]

69. Bendz, H.; Ruhland, S.C.; Pandya, M.J.; Hainzl, O.; Riegelsberger, S.; Bräuchle, C.; Buchner, J.; Issels, R.D.; Noessner, E. Human Heat Shock Protein 70 Enhances Tumor Antigen Presentation through Complex Formation and Intracellular Antigen Delivery without Innate Immune Sensing. *J. Biol. Chem.* 2007, 282, 31688–31702. [CrossRef]

70. Haug, M.; Dannecker, L.; Schepp, C.P.; Kwok, W.W.; Wernet, D.; Buckner, J.H.; Kalbacher, H.; Dannecker, G.E.; Holzer, U. The Heat Shock Protein Hsp70 Enhances Antigen-Specific Proliferation of Human CD4+ Memory T Cells. *Eur. J. Immunol.* 2005, 35, 3163–3172. [CrossRef]

71. Fischer, N.; Haug, M.; Kwok, W.W.; Kalbacher, H.; Wernet, D.; Dannecker, G.E.; Holzer, U. Involvement of CD91 and Scavenger Receptors in Hsp70-Facilitated Activation of Human Antigen-Specific CD4+ Memory T Cells. *Eur. J. Immunol.* 2010, 40, 986–997. [CrossRef] [PubMed]

72. Wang, Y.; Seidl, T.; Whittall, T.; Babaahmady, K.; Lehner, T. Stress-Activated Dendritic Cells Interact with CD4+ T Cells to Elicit Homeostatic Memory. *Eur. J. Immunol.* 2010, 40, 1628–1638. [CrossRef]

73. Wang, Y.; Rahman, D.; Lehner, T. A Comparative Study of Stress-Mediated Immunological Functions with the Adjuvantivity of Alum. *J. Biol. Chem.* 2012, 287, 17152–17160. [CrossRef] [PubMed]

74. Kane, B.A.; Bryant, K.J.; McNeil, H.P.; Tedla, N.T. Termination of Immune Activation: An Essential Component of Healthy Host Immune Responses. *J. Innate Immun.* 2014, 6, 727–738. [CrossRef] [PubMed]

75. Hirsh, M.I.; Hashiguchi, N.; Chen, Y.; Yip, L.; Junger, W.G. Surface Expression of HSP72 by LPS-Stimulated Neutrophils Facilitates Endotoxin Tolerance and Heat Shock. *J. Crit. Care* 2008, 23, 406–415. [CrossRef] [PubMed]

76. Thorsteinsdottir, J.; Stangl, S.; Fu, P.; Guo, K.; Albrecht, V.; Hennekum, A.; Luu, M.; Zanetta, S.; Coudert, B.; Bengrine, L.; et al. Monitoring HSP70 Exosomes in Cancer Patients’ Follow up: A Clinical Prospective Pilot Study. *J. Inflamm.* 2017, 22, 281–290. [CrossRef]

77. Somersni, N.; Brum, P.O.; de Miranda Ramos, V.; Gasparotto, J.; Zanotto-Filho, A.; Rostirolla, D.C.; da Silva Morrone, M.; Moreira, J.C.F.; Pêns Gelain, D. Extracellular HSP70 Activates ERK1/2, NF-κB and Pro-Inflammatory Gene Transcription Through Binding with RAGE in AS49 A549 Human Lung Cancer Cells. *Cell Physiol. Biochem.* 2017, 42, 2507–2522. [CrossRef]

78. Dar, A.A.; Patil, R.S.; Chipulkar, S.V. Insights into the Relationship between Toll Like Receptors and Gamma Delta T Cell Responses. *Front. Immunol.* 2014, 5, 366. [CrossRef]

79. Kang, H.-J.; Moon, H.-S.; Chung, H.-W. The Expression of FAS-Associated Factor 1 and Heat Shock Protein 70 in Ovarian Cancer. *Obstet. Gynecol. Sci.* 2014, 57, 281–290. [CrossRef]

80. Gao, G.; Liu, S.; Yao, Z.; Zhan, Y.; Chen, W.; Liu, Y. The Prognostic Significance of Hsp70 in Patients with Colorectal Cancer Patients: A PRISMA-Compliant Meta-Analysis. *Biomed. Res. Int.* 2021, 5526327. [CrossRef]

81. Thome, T.; Stangl, S.; Fu, P.; Guo, K.; Albrecht, V.; Hennekum, A.; Luu, M.; Zanetta, S.; Coudert, B.; Bengrine, L.; et al. Monitoring HSP70 Exosomes in Ovarian Cancer Patients’ Follow up: A Clinical Prospective Pilot Study. *J. Inflamm.* 2017, 22, 281–290. [CrossRef] [PubMed]
84. Annunziata, C.M.; Kleinberg, L.; Davidson, B.; Berner, A.; Gius, D.; Tchabo, N.; Steinberg, S.M.; Kohn, E.C. BAG-4/SODD and Associated Antia apoptotic Proteins Are Linked to Aggressiveness of Epithelial Ovarian Cancer. *Clin. Cancer Res.* 2007, 13, 6585–6592. [CrossRef] [PubMed]

85. Li, X.-F.; Hua, T.; Li, Y.; Tian, Y.-J.; Hua, Y.; Kang, S. The HSP70 Gene Predicts Prognosis and Response to Chemotherapy in Epithelial Ovarian Cancer. *Ann. Transl. Med.* 2021, 9, 806. [CrossRef] [PubMed]

86. Finkernagel, F.; Reinartz, S.; Schuldner, M.; Malz, A.; Jansen, J.M.; Wagner, U.; Worzfeld, T.; Graumann, J.; von Strandmann, E.P.; Müller, R. Dual-Platform Affinity Proteomics Identifies Links between the Recurrence of Ovarian Carcinoma and Proteins Released into the Tumor Microenvironment. *Theranostics* 2019, 9, 6601–6617. [CrossRef] [PubMed]

87. Li, Q.-L.; Bu, N.; Yu, Y.-C.; Hua, W.; Xin, X.-Y. Ex vivo Experiments of Human Ovarian Cancer Ascites-Derived Exosomes Presented by Dendritic Cells Derived from Umbilical Cord Blood for Immunotherapy Treatment. *Clin. Med. Oncol.* 2008, 2, 461–467. [CrossRef] [PubMed]

88. Klink, M.; Nowak, M.; Kielbik, M.; Bednarska, K.; Blus, E.; Szpakowski, M.; Szyll, K.; Sulowska, Z. The Interaction of HspA1A with TLR2 and TLR4 in the Response of Neutrophils Induced by Ovarian Cancer Cells in Vitro. *Cell Stress Chaperones* 2012, 17, 661–674. [CrossRef] [PubMed]

89. Adkins, I.; Sadilkova, L.; Hradilova, N.; Tomala, J.; Kovar, M.; Spisek, R. Severe, but Not Mild Heat Shock Treatment Induces Immunogenic Cell Death in Cancer Cells. *Oncoimmunology* 2017, 6, e131433. [CrossRef] [PubMed]

90. Park, G.B.; Chung, Y.H.; Kim, D. Induction of Galectin-1 by TLR-Dependent PI3K Activation Enhances Epithelial-Mesenchymal Transition of Metastatic Ovarian Cancer Cells. *Oncol. Rep.* 2017, 37, 3137–3145. [CrossRef]

91. Barreca, M.M.; Spinello, W.; Cavaliere, V.; Turturici, G.; Sconzo, G.; Kaur, P.; Tinnirello, R.; Asea, A.A.A.; Geraci, F. Extracellular Hsp70 Enhances Mesangioblast Migration via an Autocrine Signaling Pathway. *J. Cell Physiol.* 2017, 232, 1845–1861. [CrossRef] [PubMed]

92. Lee, K.-J.; Kim, Y.M.; Kim, D.Y.; Jeoung, D.; Han, K.; Lee, S.-T.; Lee, Y.-S.; Park, K.H.; Park, J.H.; Kim, D.J.; et al. Release of Heat Shock Protein 70 (Hsp70) and the Effects of Extracellular Hsp70 on Matric Metalloproteinase-9 Expression in Human Monocytic U937 Cells. *Exp. Mol. Med.* 2006, 38, 364–374. [CrossRef] [PubMed]

93. Lee, K.-H.; Jeong, J.; Yoo, C.-G. Positive Feedback Regulation of Heat Shock Protein 70 (Hsp70) Is Mediated through Toll-like Receptor 4-PI3K/Akt-Glycogen Synthase Kinase-3β Pathway. *Exp. Cell Res.* 2013, 319, 88–95. [CrossRef] [PubMed]

94. Gobbo, J.; Marcion, G.; Cordonnier, M.; Dias, A.M.M.; Pernet, N.; Hammann, A.; Richaud, S.; Mjahed, H.; Isambert, N.; Clause, N.; Clausse, V.; et al. Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide Aptamer. *J. Natl. Cancer Inst.* 2016, 108, djv330. [CrossRef] [PubMed]

95. Diao, J.; Yang, X.; Song, X.; Chen, S.; He, Y.; Wang, Q.; Chen, C.; Luo, C.; Wu, X.; Zhang, Y. Exosomal Hsp70 Mediates Immunosuppressive Activity of the Myeloid-Derived Suppressor Cells via Phosphorylation of Stat3. *Med. Oncol.* 2015, 32, 35. [CrossRef] [PubMed]

96. Chalmin, F.; Ladoire, S.; Mignot, G.; Vincent, J.; Bruchard, M.; Remy-Martin, J.-P.; Boireau, W.; Rouleau, A.; Simon, B.; Lanneau, D.; et al. Membrane-Associated Hsp72 from Tumor-Derived Exosomes Mediates STAT3-Dependent Immunosuppressive Function of Mouse and Human Myeloid-Derived Suppressor Cells. *J. Clin. Investig.* 2010, 120, 457–471. [CrossRef] [PubMed]

97. Rébé, C.; Végran, F.; Berger, H.; Giringhelli, F. STAT3 Activation: A Key Factor in Tumor Immunescape. *JAKSTAT* 2013, 2, e2010. [CrossRef]

98. Rodriguez, P.C.; Quiceno, D.G.; Zabaleta, J.; Ortiz, B.; Zea, A.H.; Piazuelo, M.B.; Delgado, A.; Correa, P.; Brayer, J.; Sotomayor, E.M.; et al. Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses. *Cancer Res.* 2004, 64, 5839–5849. [CrossRef] [PubMed]

99. Bingisser, R.M.; Tilbrook, P.A.; Holt, P.G.; Kees, U.R. Macrophage-Derived Nitric Oxide Regulates T Cell Activation via Reversible Disruption of the Jak3/STATS Signaling Pathway. *J. Immunol.* 1998, 160, 5729–5734. [PubMed]

100. Wu, F.-H.; Yuan, Y.; Li, D.; Liao, S.-J.; Yan, B.; Wei, J.-J.; Zhou, Y.-H.; Zhu, J.-H.; Zhang, G.-M.; Feng, Z.-H. Extracellular HSP70A1 Promotes the Growth of Hepatocarcinoma by Augmenting Tumor Cell Proliferation and Apoptosis-Resistance. *Cancer Lett.* 2012, 317, 157–164. [CrossRef] [PubMed]

101. De Larco, J.E.; Wuertz, B.R.K.; Furcht, L.T. The Potential Role of Neutrophils in Promoting the Metastatic Phenotype of Tumors Releasing Interleukin-8. *Clin. Cancer Res.* 2004, 10, 4895–4900. [CrossRef] [PubMed]

102. Wheeler, D.S.; Chase, M.A.; Poynter, S.E.; Wong, H.R.; Page, K. Extracellular Hsp72, an Endogenous DAMP, Is Released by Virally Infected Airway Epithelial Cells and Activates Neutrophils via Toll-like Receptor (TLR)-4. *Respir. Res.* 2009, 10, 31. [CrossRef]

103. Kelly, M.G.; Alverno, A.B.; Chen, R.; Silasi, D.-A.; Abrams, V.M.; Chan, S.; Visintin, I.; Rutherford, T.; Mor, G. TLR-4 Signaling Promotes Tumor Growth and Paclitaxel Chemoresistance in Ovarian Cancer. *Cancer Res.* 2006, 66, 3859–3868. [CrossRef] [PubMed]

104. Sapi, E.; Alverno, A.B.; Chen, W.; O’Malley, D.; Hao, X.-Y.; Dwipiyono, B.; Garg, M.; Kastmeeg, M.; Rutherford, T.; Mor, G. Resistance of Ovarian Carcinoma Cells to Docetaxel Is XIAP Dependent and Reversible by Phenoxydiazol. *Oncol. Res. Featur. Preclin. Clin. Cancer Ther.* 2014, 14, 567–578. [CrossRef]

105. Hu, W.; Xu, Z.; Zhu, S.; Sun, W.; Wang, X.; Tan, C.; Zhang, Y.; Zhang, G.; Xu, Y.; Tang, J. Small Extracellular Vesicle-Mediated Hsp70 Intercellular Delivery Enhances Breast Cancer Adriamycin Resistance. *Free Radic. Biol. Med.* 2021, 164, 85–95. [CrossRef]

106. Li, H.; Li, Y.; Liu; D.; Sun, H.; Su, D.; Yang, F.; Liu, J. Extracellular HSP70/HSP70-PCs Promote Epithelial-Mesenchymal Transition of Hepatocarcinoma Cells. *PLoS ONE* 2013, 8, e84759. [CrossRef]
107. Zhe, Y.; Li, Y.; Liu, D.; Su, D.-M.; Liu, J.-G.; Li, H.-Y. Extracellular HSP70-Peptide Complexes Promote the Proliferation of Hepatocellular Carcinoma Cells via TLR2/4/NF-kB Pathway. *Tumour Biol.* 2016, 37, 13951–13959. [CrossRef] [PubMed]

108. Rahimi, F.; Karimi, J.; Goodarzi, M.T.; Saidijam, M.; Khodadadi, I.; Razavi, A.N.E.; Nankali, M. Overexpression of Receptor for Advanced Glycation End Products (RAGE) Is Associated with Poor Prognosis in Gastric Cancer. *Cancer Biomark.* 2017, 18, 61–68. [CrossRef] [PubMed]

109. Wang, D.; Li, T.; Ye, G.; Shen, Z.; Hu, Y.; Mou, T.; Yu, J.; Li, S.; Liu, H.; Li, G. Overexpression of the Receptor for Advanced Glycation Endproducts (RAGE) in Ovarian Cancer. *PLoS ONE* 2015, 10, e0122697. [CrossRef]

110. Prantner, D.; Nallar, S.; Vogel, S.N. The Role of RAGE in Host Pathology and Crosstalk between RAGE and TLR4 in Innate Immune Signal Transduction Pathways. *FASEB J.* 2020, 34, 15659–15674. [CrossRef] [PubMed]

111. Sakaguchi, M.; Murata, H.; Yamamoto, K.; Ono, T.; Sakaguchi, Y.; Motoyama, A.; Hibino, T.; Kataoka, K.; Huh, N. TIRAP, an Adaptor Protein for TLR2/4, Transduces a Signal from RAGE Phosphorylated upon Ligand Binding. *PLoS ONE* 2011, 6, e23132. [CrossRef] [PubMed]

112. Multhoff, G.; Botzler, C.; Jennen, L.; Schmidt, J.; Ellwart, J.; Issels, R. Heat Shock Protein 72 on Tumor Cells: A Recognition Structure for Natural Killer Cells. *J. Immunol.* 1997, 158, 4341–4350.

113. Multhoff, G.; Pfister, K.; Gehrmann, M.; Hantschel, M.; Gross, C.; Hafner, M.; Hiddemann, W. A 14-Mer Hsp70 Peptide Stimulates Natural Killer (NK) Cell Activity. *Cell Stress Chaperones* 2001, 6, 337–344. [CrossRef]

114. Specht, H.M.; Ahrens, N.; Blankenstein, C.; Duell, T.; Fietkau, R.; Gaipl, U.S.; Günther, C.; Gunther, S.; Haf, G.; Hautmann, H.; et al. Heat Shock Protein 70 (Hsp70) Peptide Activated Natural Killer (NK) Cells for the Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) after Radiochemotherapy (RCTs)—From Preclinical Studies to a Clinical Phase II Trial. *Front. Immunol.* 2015, 6, 162. [CrossRef]

115. Eslner, L.; Flügge, P.F.; Lozano, J.; Muppula, V.; Eiz-Vesper, B.; Demiroglu, S.Y.; Herrmann, T.; Brunner, E.; Bickeböller, H.; et al. The Endogenous Danger Signals Heatshock 70 and MICA Cooperate in the Activation of Cytotoxic Effector Functions of NK Cells. *J. Cell. Mol. Med.* 2010, 14, 992–1002. [CrossRef]

116. Sharapova, T.N.; Romanova, E.A.; Ivanova, O.K.; Yashin, D.V.; Sashchenko, L.P. Hsp70 Interacts with the TREM-1 Receptor in the Expression of MiR-142-3p: A Negative Regulator of Heat Shock Protein 70 and Pancreatic Cancer Cell Proliferation. *Genes Cancer* 2015, 6, 144–152. [CrossRef] [PubMed]

117. Sharapova, T.N.; Romanova, E.A.; Ivanova, O.K.; Soshnikova, N.V.; Sheludchenkov, A.A.; Romanova, E.A.; Dukhanina, E.A.; Tonevitsky, A.G.; Gruchev, N.V.; Gabibov, A.G.; Georgiev, G.P.; et al. Tag7 (PGLYRP1) in Complex with Hsp70 Induces Alternative Cytotoxic Processes in Tumor Cells via TNFR1 Receptor. *J. Biol. Chem.* 2015, 290, 21724–21731. [CrossRef] [PubMed]

118. Sashchenko, L.P.; Romanova, E.A.; Ivanova, O.K.; Sharapova, T.N.; Yashin, D.V. FasL and the NKG2D Receptor Are Required for the Secretion of the Tag7/PGRP-S-Hsp70 Complex by the Cytotoxic CD8+ Lymphocytes. *IUBMB Life* 2017, 69, 30–36. [CrossRef] [PubMed]

119. Chen, T.; Guo, J.; Han, C.; Yang, M.; Cao, X. Heat Shock Protein 70, Released from Heat-Stressed Tumor Cells, Initiates Antitumor Immunity by Inducing Tumor Cell Chemokine Production and Activating Dendritic Cells via TLR4 Pathway. *J. Immunol.* 2009, 182, 1449–1459. [CrossRef]

120. Komarova, E.Y.; Marchenko, L.V.; Zhakhov, A.V.; Nikotina, A.D.; Aksenov, N.D.; Suezov, R.V.; Ischenko, A.M.; Margulis, B.A.; Guzhova, I.V. Extracellular Hsp70 Reduces the Pro-Tumor Capacity of Monocytes/Macrophages Co-Cultivated with Cancer Cells. *Int. J. Mol. Sci.* 2019, 21, 59. [CrossRef]

121. Kumar, S.; Stokes, J.; Singh, U.P.; Scissum Gunn, K.; Acharya, A.; Manne, U.; Mishra, M. Targeting Hsp70: A Possible Therapy for Cancer. *Cancer Lett.* 2016, 374, 156–166. [CrossRef]

122. Jacobson, B.A.; Chen, E.Z.; Tang, S.; Belmont, H.S.; McCauley, J.A.; Evenson, K.A.; Etchison, R.G.; Jay-Dixon, J.; Patel, M.R.; Raza, A.; et al. Triptolidine and Its Prodrug Minnelide Suppress Hsp70 and Inhibit in Vivo Growth in a Xenograft Model of Mesothelioma. *Genes Cancer* 2015, 6, 144–152. [CrossRef] [PubMed]

123. MacKenzie, T.N.; Mujumdar, N.; Banerjee, S.; Sangwan, V.; Sarver, A.; Vickers, S.; Subramanian, S.; Saluja, A.K. Triptolidine Induces the Expression of MiR-142-3p: A Negative Regulator of Heat Shock Protein 70 and Pancreatic Cancer Cell Proliferation. *Mol. Cancer Ther.* 2013, 12, 1266–1275. [CrossRef]

124. Kleinjung, T.; Arndt, O.; Feldmann, H.J.; Bockmühl, U.; Gehrmann, M.; Zilch, T.; Pfister, K.; Schönberger, J.; Marienhagen, J.; Eilles, C.; et al. Heat Shock Protein 70 (Hsp70) Membrane Expression on Head-and-Neck Cancer Biopsy-a Target for Natural Killer (NK) Cells. *Int. J. Radiat. Oncol. Biol. Phys.* 2003, 57, 820–826. [CrossRef]

125. Hantschel, M.; Pfister, K.; Jordan, A.; Scholz, R.; Andreesen, R.; Schmetzer, H.; Hiddemann, W.; Multhoff, G. Hsp70 Plasma Membrane Expression on Primary Tumor Biopsy Material and Bone Marrow of Leukemic Patients. *Cell Stress Chaperones* 2000, 5, 438–442. [CrossRef]

126. Stangl, S.; Gehrmann, M.; Rieger, J.; Kuks, K.; Riederer, I.; Sievert, W.; Hube, K.; Mocikat, R.; Dressel, R.; Kremmer, E.; et al. Targeting Membrane Heat-Shock Protein 70 (Hsp70) on Tumors by CmHsp70.1 Antibody. *Proc. Natl. Acad. Sci. USA* 2011, 108, 733–738. [CrossRef]

127. Stangl, S.; Gehrmann, M.; Dressel, R.; Alves, F.; Dullin, C.; Themelis, G.; Ntziachristos, V.; Staeblein, E.; Walch, A.; Winkelmann, L.; et al. In Vivo Imaging of CT26 Mouse Tumours by Using CmHsp70.1 Monoclonal Antibody. *J. Cell. Mol. Med.* 2011, 15, 874–887. [CrossRef]

128. Dechant, M.; Beyer, T.; Schneider-Merck, T.; Weisner, W.; Peipp, M.; van de Winkel, J.G.; Valerius, T. Effector Mechanisms of Recombinant IgA Antibodies against Epidermal Growth Factor Receptor. *J. Immunol.* 2007, 179, 2936–2943. [CrossRef]
129. Stockmeyer, B.; Dechant, M.; van Egmond, M.; Tutt, A.L.; Sundarapandian, K.; Graziano, R.F.; Repp, R.; Kalden, J.R.; Gramatzki, M.; Glennie, M.J.; et al. Triggering Fc Alpha-Receptor I (CD89) Recruits Neutrophils as Effector Cells for CD20-Directed Antibody Therapy. J. Immunol. 2000, 163, 5954–5961. [CrossRef]

130. Russell, M.W.; Reinholdt, J.; Killian, M. Anti-Inflammatory Activity of Human IgA Antibodies and Their Fab Alpha Fragments: Inhibition of IgG-Mediated Complement Activation. Eur. J. Immunol. 1989, 19, 2243–2249. [CrossRef]

131. Van der Steen, L.; Tuk, C.W.; Bakema, J.E.; Kooij, G.; Reijerkerk, A.; Vidarsson, G.; Bouna, G.; Kraal, G.; de Vries, H.E.; Beelen, R.H.J.; et al. Immunoglobulin A:Fc(Alpha)RI Interactions Induce Neutrophil Migration through Release of Leukotriene B4. Gastroenterology 2009, 137, 2018–2029. [CrossRef] [PubMed]

132. Löhse, S.; Meyer, S.; Meulenbroek, L.A.P.M.; Jansen, J.H.M.; Nederend, M.; Kretschmer, A.; Klausz, K.; Möginger, U.; Derer, S.; Rösser, T.; et al. An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo. Cancer Res. 2016, 76, 403–417. [CrossRef] [PubMed]

133. Shevtsov, M.A.; Yakovleva, L.Y.; Nikolaev, B.P.; Marchenko, Y.Y.; Dobrodumov, A.V.; Onokhin, K.V.; Onokhina, Y.S.; Selkov, S.A.; Mikhrina, A.L.; Guzhova, I.V.; et al. Tumor Targeting Using Magnetic Nanoparticle Hsp70 Conjugate in a Model of C6 Glioma. Neuro-Oncology 2014, 16, 38–49. [CrossRef] [PubMed]

134. Shevtsov, M.A.; Nikolaev, B.P.; Ryzhov, V.A.; Yakovleva, L.Y.; Marchenko, Y.Y.; Parr, M.A.; Rolich, V.I.; Mikhrina, A.L.; Dobrodumov, A.V.; Pitkin, E.; et al. Ionizing Radiation Improves Glioma-Specific Targeting of Superparamagnetic Iron Oxide Nanoparticles Conjugated with CmHsp70.1 Monoclonal Antibodies (SPION–CmHsp70.1). Nanoscale 2015, 7, 20652–20664. [CrossRef] [PubMed]

135. Huang, H.S.; Hainfeld, J.F. Intravenous Magnetic Nanoparticle Cancer Hyperthermia. Int. J. Nanomed. 2013, 8, 2521–2532. [CrossRef]

136. Shevtsov, M.; Huile, G.; Multhoff, G. Membrane Heat Shock Protein 70: A Theranostic Target for Cancer Therapy. Philos. Trans. R. Soc. B Biol. Sci. 2018, 373, 20160526. [CrossRef] [PubMed]

137. Kimm, M.A.; Shevtsov, M.; Werner, C.; Sievert, W.; Zhiyuan, W.; Schoppe, O.; Menze, B.H.; Rummeny, E.J.; Proksa, R.; Bystrova, O.; et al. Gold Nanoparticle Mediated Multi-Modal CT Imaging of Hsp70 Membrane-Positive Tumors. Cancers 2020, 12, 1331. [CrossRef]

138. Xie, Y.; Bai, O.; Zhang, H.; Yuan, J.; Zong, S.; Chibbar, R.; Slattery, K.; Qureshi, M.; Wei, Y.; Deng, Y.; et al. Membrane-Bound Hsp70-Engineered Meloma Cell-Derived Exosomes Stimulate More Efficient CD8+ CTL- and NK-Mediated Antitumor Immunity than Exosomes Released from Heat-Shocked Tumor Cells Expressing Cyttoplasmic HSP70. J. Cell. Mol. Med. 2010, 14, 2655–2666. [CrossRef] [PubMed]

139. Kim, M.S.; Haney, M.J.; Zhao, Y.; Mahajan, V.; Deygen, I.; Klyachko, N.L.; Inskoe, E.; Piroyan, A.; Sokolsky, M.; Okolie, O.; et al. Development of Exosome-Encapsulated Paclitaxel to Overcome MDR in Cancer Cells. Nanomedicine 2016, 12, 655–664. [CrossRef] [PubMed]

140. Pascucci, L.; Coccè, V.; Bonomi, A.; Ami, D.; Ceccarelli, P.; Ciusani, E.; Viganò, L.; Locatelli, A.; Sisto, F.; Doglia, S.M.; et al. Paclitaxel Is Incorporated by Mesenchymal Stromal Cells and Released in Exosomes That Inhibit in Vitro Tumor Growth: A New Approach for Drug Delivery. J. Control. Release 2014, 192, 262–270. [CrossRef] [PubMed]

141. Krause, S.W.; Gastpar, R.; Andreesen, R.; Gross, C.; Ullrich, H.; Thonigs, G.; Pfister, K.; Multhoff, G. Treatment of Colon and Lung Cancer Patients with Ex Vivo Heat Shock Protein 70-Peptide-Activated, Autologous Natural Killer Cells: A Clinical Phase I Trial. Clin. Cancer Res. 2004, 10, 3699–3707. [PubMed]

142. Multhoff, G.; Seier, S.; Stangl, S.; Sievert, W.; Shevtsov, M.; Werner, C.; Pockley, A.G.; Blankenstein, C.; Hildebrandt, M.; Offner, R.; et al. Targeted Natural Killer Cell–Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial. Clin. Cancer Res. 2020, 26, 5368–5379. [CrossRef] [PubMed]

143. Kokowski, K.; Stangl, S.; Seier, S.; Hildebrandt, M.; Vauapel, P.; Multhoff, G. Radiochemotherapy Combined with NK Cell Transfer Followed by Second-Line PD-1 Inhibition in a Patient with NSCLC Stage IIIb Inducing Long-Term Tumor Control: A Case Study. Strahlenther. Onkol. 2019, 195, 352–361. [CrossRef] [PubMed]

144. Shevtsov, M.; Pitkin, E.; Ischenko, A.; Stangl, S.; Khachatryan, W.; Galibin, O.; Edmond, S.; Lobinger, D.; Multhoff, G. Ex Vivo Hsp70-Activated NK Cells in Combination With PD-1 Inhibition Significantly Increase Overall Survival in Preclinical Models of Glioblastoma and Lung Cancer. Front. Immunol. 2019, 10, 454. [CrossRef]

145. Lin, C.-N.; Tsai, Y.-C.; Hsu, C.-C.; Liang, Y.-L.; Wu, Y.-Y.; Kang, C.-Y.; Lin, C.-H.; Hsu, P.-H.; Lee, G.-B.; Hsu, K.-F. An Aptamer Interacting with Heat Shock Protein 70 Shows Therapeutic Effects and Prognostic Ability in Serous Ovarian Cancer. Mol. Ther. Nucleic Acids 2021, 23, 757–768. [CrossRef]

146. Shevtsov, M.; Stangl, S.; Nikolaev, B.; Yakovleva, L.; Marchenko, Y.; Tagaeva, R.; Sievert, W.; Pitkin, E.; Mazur, A.; Tolstoy, P.; et al. Granzyme B Functionalized Nanoparticles Targeting Membrane Hsp70-Positive Tumors for Multimodal Cancer Theranostics. Small 2019, 15, 1900205. [CrossRef]

147. Vanaia, D.K.; Grossmann, M.E.; Celis, E.; Young, C.Y. Tumor Prevention and Antitumor Immunity with Heat Shock Protein 70 and Cancer Patients with Ex Vivo Heat Shock Protein 70-Peptide-Activated, Autologous Natural Killer Cells: A Clinical Phase I Trial. Clin. Cancer Res. 2020, 16, 403–417. [CrossRef]

148. Gong, J.; Zhang, Y.; Durfee, J.; Weng, D.; Liu, C.; Koido, S.; Song, B.; Apostolopoulos, V.; Calderwood, S.K. A Heat Shock Protein 70-Based Vaccine with Enhanced Immunogenicity for Clinical Use. J. Immunol. 2010, 184, 488–496. [CrossRef] [PubMed]

149. Trimble, C.L.; Peng, S.; Kos, F.; Gravitt, P.; Viscidi, R.; Sugar, E.; Pardoll, D.; Wu, T.C. A Phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin. Cancer Res. 2009, 15, 361–367. [CrossRef]